Bright Minds Biosciences Announces Featured Speakers for its Absence Epilepsy Virtual R&D Day on May 20, 2025

Core Opinion - Bright Minds Biosciences Inc. is focused on developing highly selective 5-HT2 agonists for treating drug-resistant epilepsy, depression, and other CNS disorders, and is hosting a virtual R&D Day featuring key opinion leaders in the field of absence seizures [1][5]. Group 1: Key Opinion Leaders - Featured speakers include Dennis Dlugos, MD, a professor of neurology and pediatrics with extensive experience in pediatric neurology and epilepsy [2]. - Wendyl D'Souza, MBChB, MPH, FRACP, PhD, is a neurologist and epilepsy specialist with over twenty years of experience, focusing on idiopathic generalized epilepsies and antiseizure medications [3]. - Alexander Rotenberg, MD, PhD, is a neurologist and epileptologist leading efforts in non-invasive brain stimulation methods for pediatric epilepsy [4]. Group 2: Company Initiatives - Bright Minds will review the therapeutic rationale for BMB-101 and discuss the BREAKTHROUGH study, an open-label Phase 2 clinical trial evaluating BMB-101's safety, tolerability, and efficacy in adult patients with classic Absence Epilepsy and Developmental and Epileptic Encephalopathy [5]. - The company is developing innovative treatments targeting neurological and psychiatric disorders, with a pipeline that includes novel compounds for conditions with high unmet medical needs [7]. - Bright Minds has created a unique platform of highly selective serotonergic agonists, providing a rich portfolio of new chemical entity programs within neurology and psychiatry [8].